Drug Trial Radar · NCT07220785
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
May 19, 2028
Study completion Sep 8, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the body at different times. This is a 2-part study: Part A is an efficacy study in pediatric and adult participants, Part B is a safety and pharmacokinetic study in pediatric participants. The study is researching several other questions, including: * How mibavademab affects the amount of sugar in the blood * How mibavademab affects the amount of fat (triglycerides) in the blood * How mibavademab affects the amount of fat that has built up in the liver * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Generalized Lipodystrophy
Interventions
MibavademabDrug
Administered as per the protocol
PlaceboDrug
Administered as per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hemoglobin A1c (HbA1c)Time frame: Through 36 weeks of exposure to mibavademab
- Percent change in fasting Triglycerides (TG)Time frame: Through 36 weeks of exposure to mibavademab
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 15 months
- Severity of TEAEsTime frame: Up to 15 months
- Concentrations of total mibavademab in serumTime frame: Up to 15 months
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Instituto Estadual de Diabetes e Endcrinologia
Rio de Janeiro, Brazil · Recruiting
Walter Cantidio University Hospital, Federal University of Ceara - Ebserh
Fortaleza, Ceará, Brazil · Recruiting
Centro de Pesquisas Clinicas de Natal (Cepclin)
Natal, Rio Grande do Norte, Brazil · Recruiting
UPCO - HCPA - Universidade Federal do Rio Grande do Sul - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Das Clinicas - School of Medicine Ribeirao Preto, University of Sao Paulo
Ribeirão Preto, São Paulo, Brazil · Recruiting
Hopital Universitaire Robert-Debre
Paris, France · Recruiting
Assistance Publique-Hopitaux de Paris (AP-HP)
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.